This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Unviersitaire De Caen, Katholieke Universiteit Leuven, National Institute of Health and Medical Research. Active years: 2019.
Company Filing History:
1 out of 1 
1 out of 631 
1 out of 1,853 
Years Active: 2019
Title: Tine Wyseure: Innovator in Thrombotic Disorder Treatments
Introduction
Tine Wyseure is a prominent inventor based in Leuven, Belgium. She has made significant contributions to the field of medical research, particularly in the treatment of thrombotic disorders. Her innovative work has led to the development of a unique bispecific inhibitor that targets specific proteins involved in blood clotting.
Latest Patents
Tine Wyseure holds a patent for her invention titled "Dual targeting of TAFI and PAI-1." This patent discloses a bispecific inhibitor designed for use in treating thrombotic disorders, including acute conditions such as stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies that target TAFI and PAI-1, demonstrating efficacy both in the presence and absence of plasminogen activators like tissue-type plasminogen activator (tPA). She has 1 patent to her name.
Career Highlights
Throughout her career, Tine has worked with esteemed institutions such as Katholieke Universiteit Leuven and the National Institute of Health and Medical Research. Her research has focused on advancing therapeutic options for patients suffering from thrombotic conditions.
Collaborations
Tine has collaborated with notable professionals in her field, including Paul Declerck and Simon De Meyer. These partnerships have contributed to her innovative research and the successful development of her patented technologies.
Conclusion
Tine Wyseure's contributions to the field of thrombotic disorder treatments highlight her role as a leading inventor. Her innovative approaches and collaborations have the potential to significantly impact patient care in this critical area of medicine.